<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028738</url>
  </required_header>
  <id_info>
    <org_study_id>H17-00161</org_study_id>
    <nct_id>NCT05028738</nct_id>
  </id_info>
  <brief_title>Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety</brief_title>
  <acronym>PORT</acronym>
  <official_title>Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive&#xD;
      transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100&#xD;
      patients with treatment resistant depression (TRD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching goal of this trial is to evaluate whether a definite adaptive pragmatic trial&#xD;
      would be feasible and establish clear go/no-go criteria as to whether proceeding to such&#xD;
      definite trial is feasible. Specific aims include 1) testing the feasibility of recruiting a&#xD;
      sample of TRD patients with less strict inclusion and exclusion criteria; 2) comparing&#xD;
      different depression and anxiety scales (both clinician-rated and self-rated) and seek input&#xD;
      from patients regarding their preferences; 3) seek input from patients with regards to the&#xD;
      use of digital phenotyping as a tool to investigate biomarkers as well as engaging in the&#xD;
      design of a potential implementation of such biomarker in a future definite trial.&#xD;
&#xD;
      Aim 1. To evaluate the feasibility of a future definite adaptive pragmatic RCT comparing left&#xD;
      vs right DLPFC repetitive transcranial magnetic stimulation (rTMS) in TRD.&#xD;
&#xD;
      Hypothesis 1a: Enrollment will be 70% of the planned target over the 1-year recruitment&#xD;
      period.&#xD;
&#xD;
      Hypothesis 1b: Retention rate of randomized participants will be ≥70% at the end of the&#xD;
      intervention in both groups.&#xD;
&#xD;
      Aim 2. To evaluate patients' preferences regarding information about treatment options when&#xD;
      there is no response to allocated treatment.&#xD;
&#xD;
      Hypothesis 2: Patients will prefer to modify treatment when there is no response.&#xD;
&#xD;
      Aim 3. To assess the feasibility of digital phenotyping as an tool to investigate biomarkers&#xD;
      in TRD.&#xD;
&#xD;
      Hypothesis 3a: Survey uptake and participation in the study regarding the use of digital&#xD;
      phenotyping will be 80% of randomized participants. Hypothesis 3b: Of those survey&#xD;
      responders, 75% will indicate they would consent to digital phenotyping in a future definite&#xD;
      RCT.&#xD;
&#xD;
      Aim 4. To develop a Bayesian statistical model that continuously updates personalized&#xD;
      treatment effect estimates as the trial progresses, and identify the circumstances under&#xD;
      which use of the model in a full-scale trial could inform treatment choice as the trial&#xD;
      progresses.&#xD;
&#xD;
      Hypothesis 4: The modeling results will identify at least one subgroup for whom early&#xD;
      stopping of the definitive trial in that subgroup may be warranted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-arm, randomized feasibility trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Single-masked (i.e. raters)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Depression severity</measure>
    <time_frame>one week post treatment</time_frame>
    <description>Inventory of Depressive Symptoms (IDS-30-SR); Minimum value per question: 0; Maximum value per question: 3; Total minimum value: 0; Total maximum value: 84; Higher score means worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Suicidal ideation</measure>
    <time_frame>one week post treatment</time_frame>
    <description>Columbia-Suicide Severity Rating Scale (C-SSRS); This questionnaire has binary responses (Yes/No). More responses with &quot;Yes&quot; mean worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety severity</measure>
    <time_frame>one week post treatment</time_frame>
    <description>Brief Symptom Inventory anxiety subscale (BSI-Anxiety); Minimum value per question: 0 (Not at all); Maximum value per question: 4 (Extremely); Total minimum value: 0; Total maximum value: 24; Higher score means worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Major Depressive Episode</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Intermittent Theta Burst Stimulation (iTBS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iTBS to the L-DLPFC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Frequency Right (LFR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1Hz stimulation to the R-DLPFC</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.</description>
    <arm_group_label>Intermittent Theta Burst Stimulation (iTBS)</arm_group_label>
    <arm_group_label>Low Frequency Right (LFR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. are outpatients;&#xD;
&#xD;
          2. are voluntary and competent to consent to treatment;&#xD;
&#xD;
          3. are ≥ 18 years;&#xD;
&#xD;
          4. have a score ≥ 26 on the IDS-30-SR;&#xD;
&#xD;
          5. have had no increase or initiation of any psychotropic medication in the 4 weeks prior&#xD;
             to screening;&#xD;
&#xD;
          6. able to adhere to the treatment schedule;&#xD;
&#xD;
          7. pass the TMS adult safety screening (TASS) questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. have active suicidal intent;&#xD;
&#xD;
          2. are pregnant;&#xD;
&#xD;
          3. have a lifetime diagnosis of schizophrenia, bipolar disorder type I, schizophreniform,&#xD;
             schizoaffective disorder or presence of psychotic symptoms within last 3 months;&#xD;
&#xD;
          4. have a concomitant major unstable medical illness;&#xD;
&#xD;
          5. have any significant form of dementia or any history of epilepsy;&#xD;
&#xD;
          6. have any intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear&#xD;
             implants, or electrodes) or any other metal object within or near the head, excluding&#xD;
             the mouth, that cannot be safely removed;&#xD;
&#xD;
          7. If participating in psychotherapy, must have been in stable treatment for at least 3&#xD;
             months prior to entry into the study, with no anticipation of change in the frequency&#xD;
             of therapeutic sessions, or the therapeutic focus over the duration of the study;&#xD;
&#xD;
          8. If they are taking psychotropic medication, be on a stable dose for 4 weeks before&#xD;
             starting treatment, and no initiation of new regular psychotropic medication;&#xD;
&#xD;
          9. have a clinically significant laboratory abnormality, in the opinion of the one of the&#xD;
             principal investigators;&#xD;
&#xD;
         10. have a non-correctable clinically significant sensory impairment (i.e., cannot hear&#xD;
             well enough to cooperate with interview).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fidel Vila-Rodriguez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Afifa Humaira, BSc</last_name>
    <phone>604-827-1361</phone>
    <email>afifa.humaira@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Avina, BSc</last_name>
    <phone>604-827-1361</phone>
    <email>michelle.avina@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Non-Invasive Neurostimulation Therapies (NINET) Laboratory, UBC Department of Psychiatry</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afifa Humaira, B.Sc.</last_name>
      <phone>604-822-7308</phone>
      <email>afifa.humaira@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Fidel Vila-Rodriguez, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Fidel Vila-Rodriguez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pragmatic</keyword>
  <keyword>Patient-oriented research</keyword>
  <keyword>TMS</keyword>
  <keyword>Treatment-resistant depression</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>rTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

